Background: Poorly controlled HIV infection is associated with increased risk of COPD. Acute exacerbations of COPD (AECOPD) are major contributors to morbidity and mortality but are understudied in HIV populations. Within the AIDS Linked to the Intravenous Experience (ALIVE) study, we examined the factors associated with AECOPD among those with and at-risk for HIV infection. Methodology: ALIVE is an on-going prospective, community-based cohort that began following persons with a history of injecting drugs in Baltimore, MD in 1988. We longitudinally examined 167 individuals who had pre-bronchodilator airflow obstruction (defined as forced expiratory volume in 1 second/ forced vital capacity [FEV1/FVC] <0.70) on all spirometry measures performed during follow-up. AECOPD, assessed at each 6 month study visit, was defined as answering “yes” to the question “In the last 6 months, have you had a worsening of your breathing status requiring treatment with antibiotics or steroids?” Multivariable logistic regression with generalized estimating equations was used to identify correlates of AECOPD. Results: A total of 167 participants with a median of 3 visits (IQR 2-5) over 1.5 years (IQR: 0.5-2.1) were included in analysis. The mean age at baseline was 52 years, 89% were black, 30% female and 32% HIV infected with a median CD4 count of 312 cells/mL (IQR: 193-454) and a median viral load of 40 copies/mL (IQR: 40-3627). After adjusting for gender, comorbidity, and COPD severity, HIV infection was independently associated with a 2.49 increased odds of AECOPD (Table 1). Compared to HIV negatives, HIV-infected persons with undetectable (≤40 copies/mL) and high (>10,000 copies/mL) HIV RNA had increased odds of AECOPD, but intermediate RNA levels were not associated (OR 1.23; 95% CI 0.32, 4.67; p=0.76). CD4 count was not associated with increased odds of AECOPD. Conclusions: HIV infection was independently associated with increased odds of AECOPD. Increased risk for AECOPD at higher and at lower HIV RNA levels likely reflects both biological (immune dysregulation) and behavioral (access to HIV and COPD care) patterns. Providers should be aware that HIV infection may increase the risk for AECOPD.